Monitor the registration statement filing and effectiveness timeline; failure triggers 2% monthly penalties. The second tranche closing and stockholder approval vote (due within 75 days) are key catalysts. The variable conversion price at a deep discount to market creates persistent overhang.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $1.31entry
- T+1 · 5d ago −0.76%α −0.41% · $1.30
- T+4 · todayOpen
- T+5 · in 13h Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Alzamend Neuro filed an 8-K/A amending its July 2026 securities purchase agreement with Ault Lending, LLC. The total financing was reduced from $25M to $10M, with $7.5M already closed in July and a second $2.5M tranche to close upon SEC effectiveness of a resale registration statement. The Series D preferred shares carry a conversion price floor of $0.2668 and a variable conversion discount of 80% of the lowest 5-day closing bid, creating potentially massive dilution relative to the company's $7M market cap.
Key Facts
- Original $25M financing reduced to $10M; $7.5M already sold in July 2026, $2.5M second tranche pending.
- Second tranche closing conditioned on SEC effectiveness of registration statement and stock price above $0.2668 floor.
- Conversion price is the greater of $0.2668 or 80% of the lowest 5-day closing bid, capped at $2.00.
- Company must seek stockholder approval for conversion shares exceeding 19.99% of outstanding common stock.
- Registration statement must be filed by November 17, 2026; failure triggers 2% monthly liquidated damages (max 15%).
- Purchaser has right of first refusal and 33.33% participation right in future equity offerings for 3 years.
- Most-favored-nation clause: any better terms in future financings automatically apply to this purchaser.
- Company market cap is $7M; potential conversion shares could massively dilute existing holders.
Financial Impact
Up to $10M in Series D preferred sold; $7.5M already received. Conversion shares could exceed 19.99% of outstanding common, requiring stockholder approval. Dilution from full conversion at $0.2668 floor would be enormous relative to $7M market cap.
Risk Factors
- Massive potential dilution from conversion of Series D preferred at deeply discounted variable price.
- Registration statement delays could trigger escalating cash penalties.
- Stockholder approval may not be obtained, limiting conversion and voting rights.
- Company has only $7M market cap; additional $2.5M tranche and $10M additional investment right could overwhelm equity base.
- Most-favored-nation and participation rights give purchaser significant control over future financings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001214659-26-013930 |
| Exhibit: ex10_2.htm | 0001214659-26-013930 |
| Exhibit: ex3_1.htm | 0001214659-26-013930 |
| Document: o11102668ka1.htm | 0001214659-26-013930 |
Track record
6 reports on ALZN
Filters
- Nov 17, 2026today S-3 Bearish 7/10 Entry $1.11 Now $1.13 −1.80% settles Nov 19
- Nov 17, 2026today 8-K Bearish 6/10 Entry $1.14 Now $1.13 +0.88% settles Nov 19
- Nov 10, 20267d ago 8-K/A Bearish 7/10 Viewing Entry $1.31 to $1.30 Now $1.13 +13.74% ▲ +0.76% +0.41% vs SPY
- Sep 29, 20267w ago 8-K Neutral 3/10 Entry $1.82 to $1.73 Now $1.13 −37.91% ▼ −4.95% −4.74% vs SPY
- Aug 4, 202614w ago 3 Neutral 2/10 Entry $1.43 to $1.38 Now $1.13 −20.98% ▼ −3.50% −3.34% vs SPY
- Feb 26, 202637w ago DEFA14A Neutral 4/10 Entry $2.01 to $2.01 Now $1.13 −43.78% · 0.00% −0.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers